CG Oncology, Inc Common stock

Yahoo Finance • 21 days ago

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment - - 90%... Full story

Yahoo Finance • 23 days ago

CG Oncology Completes Enrollment in PIVOT-006

– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) – – One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per... Full story

Yahoo Finance • 28 days ago

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients w... Full story

Yahoo Finance • last month

Piper Sandler initiates CG Oncology stock coverage with Overweight rating

Investing.com - Piper Sandler initiated coverage on CG Oncology (NASDAQ:CGON) with an Overweight rating and a price target of $55.00 on Tuesday. The company, currently valued at $1.96 billion, trades at $26.13, with analyst targets rangi... Full story

Yahoo Finance • 2 months ago

CG Oncology GAAP EPS of -$0.54

* CG Oncology press release [https://seekingalpha.com/pr/20194834-cg-oncology-reports-second-quarter-2025-financial-results-and-provides-business-updates] (NASDAQ:CGON [https://seekingalpha.com/symbol/CGON]): GAAP EPS of -$0.54. * Cash... Full story

Yahoo Finance • 2 months ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated CORE-008 Cohort CX evaluating t... Full story

Yahoo Finance • 3 months ago

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers e... Full story

Yahoo Finance • 4 months ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients w... Full story

Yahoo Finance • 4 months ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M - - Promising early signal in Cohort P with 90.5% high-grade r... Full story

Yahoo Finance • 5 months ago

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from... Full story

Yahoo Finance • 6 months ago

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Mo... Full story

Yahoo Finance • 7 months ago

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients... Full story

Yahoo Finance • 7 months ago

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients a... Full story